On September 18th, OBIO organized a workshop with two industry experts and provided the CFO perspective on budgeting for start-up and growing health science companies.
John Jordan (CFO, RNA Diagnostics) and Jim Cooke (Partner, Stoneybridge Partners) addressed 3 main areas – how to build a robust budget, how to present a budget to the board and to investors and how to manage a budget.
On Wednesday, September 5th, OBIO hosted Toshio Sugano, the Chief Investment Officer of the Biomedical Development Board of Taiwan, who met with a collection of Canada’s most esteemed investors and some of its highest potential health science companies.
If you are considering hiring a new graduate or intern this coming January, it is a good idea to get started now. OBIO H2BB is constantly sourcing new early career talent from top business and innovation programs.
On Tuesday, August 27th, OBIO hosted a delegation of distinguished scientists from National Cheng Kung University to meet with representatives from the Ontario health science industry including OIRM and CCRM, and the provincial government.
OBIO has pre-screened 18 business-experienced candidates ready to help your company scale and grow. These high-quality recent business (MBA; M.Mgmt; M. Mgt Innovation, etc.) graduates and co-op students have the Business Development skills you need.
OBIO is proud to announce its 2018 Capital Access Advisory Program (CAAP®) and the 11 high-potential health companies in this year’s cohort. Now in its sixth year, this year’s OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives which will position them for successful financing.
The Ontario Bioscience Innovation Organization (OBIO®) released its latest report, ‘Use It or Lose It: Industry Solutions to Ontario’s Commercialization Gap’, with recommendations from health science company executives on how to create the conditions for the growth of Ontario’s health science industry.
Ontario Bioscience Innovation Organization (OBIO®), a not-for-profit membership based organization that is Ontario’s leading advocate for the health science industry, announced today that Ontario health science companies that have participated in its Capital Access Advisory Program (CAAP®) have raised more than $109 Million since the CAAP program launched in 2013.
January 24, 2017 TORONTO--(BUSINESS WIRE)--The Ontario Bioscience Innovation Organization (OBIO®) hosted a summit of industry, academic, government and investment leaders about the future of health science innovation in Canada. Attendees engaged in group discussions and heard from subject matter experts to extrapolate a mandate of action for anchoring health science companies in Ontario. The outcome of the summit lays a foundation for actionable business cases for private and public sector solutions to the health science industry’s biggest challenges: Innovation Pull, Adoption and Capital Attraction.
Versant Ventures has announced the close of its newest fund, Versant Venture Capital VI, at its hard cap of CAD538 million (USD400 million). Versant will use its diversified global investment strategy to find, form and fund innovative healthcare companies with an emphasis on novel therapeutics.
OBIO and Blakes hosted OBIO's third annual pre-RESI networking event, connecting high potential companies with global investors. Over 100 international investors, local investors and strategics, as well as executives from high potential Ontario health science companies
OBIO - in partnership with Accel-Rx - hosted the Niagara Health Science Emerging Company Forum, which brought together CEOs and senior executives from high potential Canadian health science companies with senior leadership from American investors and strategics.
On October 24th, OBIO hosted Health Economics Day workshop in partnership with St. Michael’s Hospital.
The workshop took place in the auditorium at the Li Ka Shing Knowledge Institute and featured four sessions: a moderated panel discussion with four panellists, followed by three presentations by three health economics experts.
Recently, the Minister of Innovation, Science and Economic Development launched a cross country tour to introduce the nine supercluster proposals that have been shortlisted by the federal government for the Innovation Superclusters Initiative.
Grant Burns, OBIO's Public Affairs and Communications Manager, has listed the 9 proposals and provided commentary and analysis on how they relate to the health technology sector.
Bridging the Talent Gap reports on the unique value of OBIO’s Health to Business Bridge (H2BB) business internship program. This report describes how H2BB addresses the challenge of pulling top talent into Ontario’s health science industry to address the talent gap identified by 96% of Ontario’s health science company CEOs.
The “Tackling the Anchor Company Challenge Summit”, assembled industry, academic, government and investment leaders committed to working together to create a mandate of action for anchoring health science companies in Ontario.
In 2017, the Ontario Bioscience Innovation Organization convened a working group (‘OBIO Tax Policy Working Group’, OTPWG) of health science industry leaders and tax experts from academia and the private sector to examine Canada’s tax incentives and their effectiveness in stimulating growth in the health science industry.
"The Ontario Bioscience Innovation Organization (OBIO) strongly believes that the supply chain of the future must incorporate a formal approach to creating pathways for the adoption and procurement of innovation, to benefit the people of Ontario from both a health and economic perspective."
2016 has already been a productive year for OBIO as we push forward on our advocacy efforts, expand our Health Science networks and partnerships and continue to provide access to capital for Ontario Health Science companies in order for them to reach the next level.
The Centre for Aging + Brain Health Innovation (CABHI), led by Baycrest and in partnership with National Bank, announced the launch of a new Mentorship, Capital and Continuation Program (MC2). MC2 will accelerate market-ready healthcare innovations for the aging population from bench to bedside more quickly and efficiently.
Trexo Robotics (OBIO Pre-CAAP 2018 Company) was featured as one of The 10 Most Innovative Medical Devices Companies in 2018 by Insights Care, a publication that covers important issues and trends shaping the future of the healthcare industry.
Charles Plant at the Impact Centre, in partnership with Openview and Communitech, examined thousands of software companies to uncover their secrets to driving growth. The published report sets out important growth metrics, particularly relevant for companies selling Software as a Service (SaaS).